Skip to main content

Clinical Trials

The Department of Psychiatry & Behavioral Sciences welcomes research participants ages 12 to 70 to enroll in studies aimed at improving the diagnosis and treatment of schizophrenia, bipolar disorder, Alzheimer’s disease, depression and anxiety. Browse the entries below and call the associated telephone numbers to learn how you can volunteer to help advance our understanding of psychiatric illness.

If you have questions, please call the Clinical Research Program office at 312-503-9100.

Feinberg Clinical Trials

Scientists at the medical school are conducting hundreds of clinical trials daily. Learn more about all our work via the Feinberg Office of Research Clinical Trials page. Search for trials by disease or condition.

Trials

Northwestern University The Department of Psychiatry and Behavioral Sciences, Clinical Research Program (NU CRP) Recruitment Pipeline

The recruitment pipeline provides research staff with an organized system of identifying researchsubjects.NU CRP clinical research studies covers a wide spectrum of Axis I Diagnoses such as schizophrenia, depression, anxiety, etc. NU CRP also conducts research studies for patients who are diagnosed with certain neurological diseases such as Alzheimer’…
The recruitment pipeline provides research staff with an organized system of identifying researchsubjects.NU CRP clinical research studies covers a wide spectrum of Axis I Diagnoses such as schizophrenia, depression, anxiety, etc. NU CRP also conducts research studies for patients who are diagnosed with certain neurological diseases such as Alzheimer’s disease, Tourette’s Syndrome, etc. NU CRP conducts basic, translational and clinical research. Personal Health Information (PHI) will not be collected. All information collected in this recruitmentregistry is based on the patient self-report. You will be contacted to answer additional questions by someone in the study staff and to determine your eligibility for the current studies.
Goldman, Morris BGoldman, Morris B
  • Map it 680 N. Lake Shore Dr.
    Chicago, IL
STU00059328
More Info
Copy

LiveWell: A Mobile Intervention for Bipolar Disorder

This study is being done to evaluate the use of a mobile phone intervention for bipolar disorder that aims to improve patient self-management and increase the effectiveness of psychological interventions. The goal is to reduce symptoms and prevent relapse in people with bipolar disorder. If you are eligible for …
This study is being done to evaluate the use of a mobile phone intervention for bipolar disorder that aims to improve patient self-management and increase the effectiveness of psychological interventions. The goal is to reduce symptoms and prevent relapse in people with bipolar disorder. If you are eligible for the study, your participation will last up to 12 months.
Individuals 18-65 years old who have been diagnosed with bipolar disorder and are currently working with a psychiatrist
Goulding, Evan HGoulding, Evan H
  • Map it 680 N. Lake Shore Dr.
    Chicago, IL
NCT03088462 STU00202860
More Info
Copy

The EMPOWER Study: A new drug treatment for schizophrenia

The primary goal of the study is assessing the study medication oral emraclidine to possibly treat schizophrenia in adult participants with schizophrenia when taken over a year.Emraclidine is a brain penetrant muscarinic acetylcholine receptor (mAChR) activator that selectively binds to the M4 muscarinic receptor subtype while sparing other muscarinic …

The primary goal of the study is assessing the study medication oral emraclidine to possibly treat schizophrenia in adult participants with schizophrenia when taken over a year.

Emraclidine is a brain penetrant muscarinic acetylcholine receptor (mAChR) activator that selectively binds to the M4 muscarinic receptor subtype while sparing other muscarinic receptor subtypes (M1, M2, M3, and M5). Emraclidine is being developed for treatment of psychosis in schizophrenia.

This study is for individuals who have been diagnosed with schizophrenia.

18-65years

Rado, Jeffrey ThomasRado, Jeffrey Thomas
  • Map it 680 N. Lake Shore Dr.
    Chicago, IL
NCT05443724 STU00218679
More Info
Copy

CT-155-R-001 Digital Mental Heath App study

This is a digital mental health application study involving digital therapeutic CT-155 as an added treatment to standard antipsychotic therapy in adult participants with negative symptoms of schizophreniaThe purpose of the proposed study is to evaluate the efficacy and safety of two prescription digital therapeutics as an additional treatment …

This is a digital mental health application study involving digital therapeutic CT-155 as an added treatment to standard antipsychotic therapy in adult participants with negative symptoms of schizophrenia

The purpose of the proposed study is to evaluate the efficacy and safety of two prescription digital therapeutics as an additional treatment to the regular care in patients diagnosed with experiential negative symptoms of schizophrenia.

Eligibility: 18 years of age or older , Diagnosed with Schizophrenia Study duration=16 weeks

Rado, Jeffrey ThomasRado, Jeffrey Thomas
  • Map it 680 N. Lake Shore Dr.
    Chicago, IL
NCT05838625 STU00218871
More Info
Copy

Follow Psychiatry on